On the HCPLive Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.
May 17th 2024
HCV testing was accepted by more than 80% of patients undergoing mammography and resulted in prompt linkage to care.
Recommendations to Improve Liver Health in Hepatitis B, Hepatitis C Patients
July 11th 2014Although it is widely understood that hepatitis B virus (HBV) and hepatitis C virus (HCV) are the leading causes of liver cirrhosis and liver cancer, an alarming number of HBV and HCV carriers have unhealthy habits that result in poor liver health.
Telaprevir Treatment Decays Hepatitis C Virus Faster in Blood than Liver
June 25th 2014A recent study found that the hepatitis C virus decays during treatment with telaprevir faster in the bloodstream than it does in the liver, a discovery that could help pinpoint how long a patient needs to take medicine to rid the virus from the body.
Serious Liver Disease Rates Higher Among Coinfected Patients
June 19th 2014Study results show hepatic decompensation is more common in people who have both HIV and hepatitis C virus (HCV) compared to those infected only with HCV, an indication that early HCV treatment among coinfected patients is needed.
FDA Gives the Green Light for Achillion to Resume Trials with Sovaprevir for Hepatitis C
June 13th 2014The US Food and Drug Administration partially lifted a clinical hold on a hepatitis C drug under development by Achillion Pharmaceuticals, clearing the way for a restart of the company's clinical trials of sovaprevir.
Hepatitis Awareness Blitz Marks 25th Year Anniversary Discovery
May 28th 2014Noting that this year marks the 25th anniversary of the discovery of hepatitis C, health officials ramped up a public awareness campaign during the month of May to encourage more testing for hepatitis among at-risk populations.
Novel Hepatitis C Treatment Produces 'Out-of-the-ballpark' Cure Rates in Cirrhosis Patients
An oral, interferon-free regimen comprised of several agents cured hepatitis C in more than 90% of patients who also had liver cirrhosis, according to the results of an international study.
Project ECHO Expands Reach of Hepatitis C Treatment in Underserved Rural Areas
May 15th 2014A project to expand hepatitis C treatment by equipping primary care doctors with telemedicine tools more than doubled the proportion of patients expected to receive treatment in Arizona and Utah, according to a recently released government report.
All-oral Drug Combination Delivers High Hepatitis C Cure Rates
May 12th 2014An all-oral antiviral drug combination that included ombitasvir and dasabuvir with and without ribavirin resulted in high cure rates among patients with hepatitis C virus infections in first-time treatments for the disease, according to an article published in the May 4, 2014, issue of the New England Journal of Medicine.
Triple Antiviral Therapy Achieves Near 100% Response in Patients with Hepatitis C Genotype 4
May 6th 2014An all-oral, ribavirin-free, interferon-free combination of three direct-acting antiviral agents that had achieved sustained virologic response in 92% of patients with chronic HCV genotype 1 infection has demonstrated even greater response in patients with genotype 4 infection.
Combination Treatment with Sofosbuvir plus Ledipasvir Highly Effective After Only Eight Weeks
May 6th 2014Treatment with an 8-week regimen of combination sofosbuvir plus ledipasvir with or without ribavirin produced sustained virologic response rates (SVR) similar to those achieved with a 12-week regimen in non-cirrhotic, previously untreated, genotype 1 hepatitis C patients, according to results from the ION-3 trial.
Study Provides More Evidence that Statins Help Slow Liver Fibrosis in Hepatitis C
May 5th 2014Patients in the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial who were also treated with statins experienced a significant decrease in time to histological disease progression compared to patients who did not receive statin treatment.
Approval of Newer, More Effective Hepatitis C Drugs Means a Cure Is Within Reach for Most Patients
May 5th 2014Within the next two years, treatments for hepatitis C with 95% cure rates that are all-oral, interferon-free, and effective within 12 weeks or less with negligible side effects will be readily available.
The Power of 'Big Data' and the Impact of Screening on Hepatitis C Survival Rates
April 15th 2014A large multinational observational study of patients with hepatitis C reveals etiology does not play a major role in HCV survival rates and that early detection and access to treatment have a greater impact.
New Treatment Options for Patients with Hepatitis C Genotype 4
April 12th 2014Data from the PEARL-I trial of patients with hepatitis C genotype 4 show high rates of sustained virologic response at 12 weeks associated with combination treatment with ABT-450 (a protease inhibitor boosted by ritonavir) and ombitasvir.